Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells 1,664 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 1,664 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $11.20, for a total value of $18,636.80. Following the completion of the sale, the chief executive officer now owns 77,454 shares in the company, valued at approximately $867,484.80. The trade was a 2.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA opened at $10.54 on Friday. Atara Biotherapeutics, Inc. has a 52-week low of $6.50 and a 52-week high of $39.50. The business’s fifty day moving average is $9.14 and its 200 day moving average is $10.11. The firm has a market cap of $60.68 million, a price-to-earnings ratio of -0.41 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same quarter in the prior year, the company earned ($16.50) earnings per share. Equities analysts predict that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. Finally, Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Atara Biotherapeutics has an average rating of “Hold” and a consensus target price of $16.67.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics in the second quarter worth $79,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Atara Biotherapeutics during the second quarter worth about $53,000. Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 4,043 shares during the last quarter. State Street Corp raised its holdings in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the last quarter. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.